For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease
Clinical stage drug developer Syntara1 today announced that the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease.
The first patient has been dosed in Sydney in a multi-national trial that is majority funded by the Parkinson’s Virtual Biotech, the international drug discovery and development program founded by Parkinson’s UK.